Publications

Keylor MH, Gulati A, Kattar SD, … Ciaccio PJ, et al. 2022. Structure-guided discovery of aminoquinazolines as brain-penetrant and selective LRRK2 inhibitors. J Medicinal Chem 65(1):838–856.

Anmol G, Yeung CS, Lapointe B, … Ciaccio P, et al. 2021. Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors. RSC Medicinal Chemistry 12(7):1164–1173.

Bryce DK, Ware CM, Woodhouse JD, Ciaccio PJ, et al. 2021. Characterization of the onset, progression, and reversibility of morphological changes in mouse lung after pharmacological inhibition of leucine-rich kinase 2 kinase activity. J Pharmacol Exp Ther 377(1):11–19.

Reck F, Ehmann DE, Dougherty TJ, … Ciaccio P, et al. 2014. Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity against Pseudomonas aeruginosa. Bioorg Medicinal Chem 22(19):5392–5409.

Chang JCF, Ciaccio P, Schroeder P, Wright L, Westwood R, Berg A-L. 2014. Pathology and neurotoxicity in dogs after repeat dose exposure to a serotonin 5-HT1b inhibitor. J Toxicol Pathol 27(1):31–42.

014 Keirstead ND, Wagoner MP, Bentley P, Blais M, Brown C, Cheatham L, Ciaccio P, et al. 2014. Early prediction of polymyxin-induced nephrotoxicity with next generation urinary kidney injury biomarkers. Toxicol Sci 137(2):278.

Morelli J, Ciaccio PJ. 2013. Differential cytotoxicity responses by dog and rat hepatocytes to phospholipogenic treatments. J Toxicol, Article ID 956404.

Reck F, Alm R, Brassil P, Newman J, Ciaccio P, et al. 2012. Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: Antibacterial agents with an improved safety profile. J Medicinal Chem 54(22):7834–7847.

Barone LR, Boyer S, Damewood JR Jr, Fikes J, Ciaccio PJ. 2012. Phospholipogenic pharmaceuticals are associated with a higher incidence of histological findings than non-phospholipogenic pharmaceuticals in preclinical toxicology studies. J Toxicol, Article ID:308594.

Bernstein, PR, Ciaccio P, Morelli J. 2011. Drug-induced phospholipidosis. Ann Rep Medicinal Chem. 46:419–431.

Brown D, Maier DL, Sylvester MA, … Ciaccio PJ, et al. 2011. 2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity. Bioorg Med Chem Lett 21(11):3399–3403.

Morelli JK, Buehrle M, Pognan F, Barone LR, Fieles W. Ciaccio PJ. 2006. Validation of an in vitro screen for phospholipidosis using a high content biology platform. Cell Biol Toxicol 22:15–27.

Milano J, McKay J, Dagenais C, … Ciaccio PJ. 2004. Modulation of notch processing by g-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol Sci 82:341–358.

Shockor JP, Espina R, Car BD, Contel E, Ciaccio PJ, Lindon J, Holmes E, Nicholson J. 2001. Detection of in vivo biomarkers of phospholipidosis using NMR-based metabonomic approaches. Magnet Resonance Chem
39:559–565.

Glatt C, Davis LG, Ladics GS, Ciaccio PJ, Slusher LB. 2001. An evaluation of the DNA array for use in toxicological studies. Toxicol Methods 11:247–275.

Car, BD, Ciaccio PJ, Contel NR. 2001. Application of new technologies to toxicologic pathology. Toxicol Pathol, DOI:10.1016/B978-012330215-1/50012-0.

Ciaccio PJ, Gicquel E, O’Neill PJ, Vandenberghe YL. 1998. Investigation of the positive response of ethyl acrylate in the mouse lymphoma genotoxicity assay. Toxicol Sci 46:324–332.

Ranganathan S, Ciaccio PJ, Walsh ES, Tew KD. 1999. Genomic sequence of human glyoxalase I: Analysis of promoter activity and its regulation. Gene 240:149–155.

Ciaccio PJ, Shen H, Jaiswal AK, Lyttle MH, Tew KD. 1995. Modulation of detoxification gene expression in HT29 colon cells by glutathione S-transferase inhibitors. Molec Pharmacol 48:639–647

Ciaccio PJ, Walsh ES, Tew KD. 1996. Promoter analysis of a human dihydrodiol dehydrogenase. Biochem Biophys Res Comm 228(2):524–529.